With previous studies demonstrating ARF’s ability to activate innate and adaptive immune responses within cancer cells to suppress tumorigenesis in vivo, ARF-targeting strategies present opportunities to augment existing cancer immunotherapies (Yetil et al., 2015; Cerqueira et al., 2020). The gene discussed is CDKN2A; the disease is cancer.